Literature DB >> 26691834

The indirect pathway of the nucleus accumbens shell amplifies neuropathic pain.

Wenjie Ren1, Maria Virginia Centeno1, Sara Berger1, Ying Wu2, Xiaodong Na2, Xianguo Liu2, Jyothisri Kondapalli1, A Vania Apkarian1, Marco Martina1, D James Surmeier1.   

Abstract

We examined adaptations in nucleus accumbens (NAc) neurons in mouse and rat peripheral nerve injury models of neuropathic pain. Injury selectively increased excitability of NAc shell indirect pathway spiny projection neurons (iSPNs) and altered their synaptic connectivity. Moreover, injury-induced tactile allodynia was reversed by inhibiting and exacerbated by exciting iSPNs, indicating that they not only participated in the central representation of pain, but gated activity in ascending nociceptive pathways.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26691834      PMCID: PMC4889808          DOI: 10.1038/nn.4199

Source DB:  PubMed          Journal:  Nat Neurosci        ISSN: 1097-6256            Impact factor:   24.884


  24 in total

1.  Distinct roles of synaptic transmission in direct and indirect striatal pathways to reward and aversive behavior.

Authors:  Takatoshi Hikida; Kensuke Kimura; Norio Wada; Kazuo Funabiki; Shigetada Nakanishi
Journal:  Neuron       Date:  2010-06-24       Impact factor: 17.173

Review 2.  Diversity in NMDA receptor composition: many regulators, many consequences.

Authors:  Antonio Sanz-Clemente; Roger A Nicoll; Katherine W Roche
Journal:  Neuroscientist       Date:  2012-02-17       Impact factor: 7.519

3.  Predicting value of pain and analgesia: nucleus accumbens response to noxious stimuli changes in the presence of chronic pain.

Authors:  Marwan N Baliki; Paul Y Geha; Howard L Fields; A Vania Apkarian
Journal:  Neuron       Date:  2010-04-15       Impact factor: 17.173

4.  Chronic dizocilpine or apomorphine and development of neuropathy in two rat models I: behavioral effects and role of nucleus accumbens.

Authors:  Rani Sarkis; Nayef Saadé; Samir Atweh; Suhayl Jabbur; Hassen Al-Amin
Journal:  Exp Neurol       Date:  2010-12-10       Impact factor: 5.330

Review 5.  Modulation of striatal projection systems by dopamine.

Authors:  Charles R Gerfen; D James Surmeier
Journal:  Annu Rev Neurosci       Date:  2011       Impact factor: 12.449

Review 6.  Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.

Authors:  Dirk Deleu; Margaret G Northway; Yolande Hanssens
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

7.  Quantitative assessment of tactile allodynia in the rat paw.

Authors:  S R Chaplan; F W Bach; J W Pogrel; J M Chung; T L Yaksh
Journal:  J Neurosci Methods       Date:  1994-07       Impact factor: 2.390

8.  Chronic pain. Decreased motivation during chronic pain requires long-term depression in the nucleus accumbens.

Authors:  Neil Schwartz; Paul Temkin; Sandra Jurado; Byung Kook Lim; Boris D Heifets; Jai S Polepalli; Robert C Malenka
Journal:  Science       Date:  2014-08-01       Impact factor: 47.728

9.  Parceling human accumbens into putative core and shell dissociates encoding of values for reward and pain.

Authors:  Marwan N Baliki; Ali Mansour; Alex T Baria; Lejian Huang; Sara E Berger; Howard L Fields; A Vania Apkarian
Journal:  J Neurosci       Date:  2013-10-09       Impact factor: 6.167

10.  Synaptic and behavioral profile of multiple glutamatergic inputs to the nucleus accumbens.

Authors:  Jonathan P Britt; Faiza Benaliouad; Ross A McDevitt; Garret D Stuber; Roy A Wise; Antonello Bonci
Journal:  Neuron       Date:  2012-11-21       Impact factor: 17.173

View more
  76 in total

Review 1.  The risk for problematic opioid use in chronic pain: What can we learn from studies of pain and reward?

Authors:  Patrick H Finan; Bethany Remeniuk; Kelly E Dunn
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-08-01       Impact factor: 5.067

Review 2.  Peripheral and central viewpoints of chronic pain, and translational implications.

Authors:  A Vania Apkarian; Diane Reckziegel
Journal:  Neurosci Lett       Date:  2018-11-29       Impact factor: 3.046

3.  Reduced ΔFosB expression in the rat nucleus accumbens has causal role in the neuropathic pain phenotype.

Authors:  Sarah L Pollema-Mays; Maria Virginia Centeno; Zheng Chang; A Vania Apkarian; Marco Martina
Journal:  Neurosci Lett       Date:  2018-11-29       Impact factor: 3.046

Review 4.  Cortico-limbic pain mechanisms.

Authors:  Jeremy M Thompson; Volker Neugebauer
Journal:  Neurosci Lett       Date:  2018-11-29       Impact factor: 3.046

5.  Alpha-phase synchrony EEG training for multi-resistant chronic low back pain patients: an open-label pilot study.

Authors:  Louis Mayaud; Hélène Wu; Quentin Barthélemy; Patrick Favennec; Yannick Delpierre; Marco Congedo; Arnaud Dupeyron; Michel Ritz
Journal:  Eur Spine J       Date:  2019-06-28       Impact factor: 3.134

Review 6.  Corticolimbic circuitry in the modulation of chronic pain and substance abuse.

Authors:  Anna M W Taylor
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-05-10       Impact factor: 5.067

7.  Methylphenidate and Morphine Combination Therapy in a Rat Model of Chronic Pain.

Authors:  Zerong You; Weihua Ding; Jason T Doheny; Shiqian Shen; Jinsheng Yang; Liuyue Yang; Lucy Chen; Shengmei Zhu; Jianren Mao
Journal:  Anesth Analg       Date:  2020-02       Impact factor: 5.108

Review 8.  Chemogenetic Tools for Causal Cellular and Neuronal Biology.

Authors:  Deniz Atasoy; Scott M Sternson
Journal:  Physiol Rev       Date:  2018-01-01       Impact factor: 37.312

9.  Loss of M1 Receptor Dependent Cholinergic Excitation Contributes to mPFC Deactivation in Neuropathic Pain.

Authors:  Daniel Radzicki; Sarah L Pollema-Mays; Antonio Sanz-Clemente; Marco Martina
Journal:  J Neurosci       Date:  2017-01-30       Impact factor: 6.167

10.  Circuit-selective properties of glutamatergic inputs to the rat prelimbic cortex and their alterations in neuropathic pain.

Authors:  Crystle J Kelly; Marco Martina
Journal:  Brain Struct Funct       Date:  2018-03-17       Impact factor: 3.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.